HC Wainwright Issues Pessimistic Outlook for AVDL Earnings

Avadel Pharmaceuticals plc (NASDAQ:AVDL) – Research analysts at HC Wainwright decreased their Q2 2025 earnings per share estimates for shares of Avadel Pharmaceuticals in a research note issued on Tuesday, March 4th. HC Wainwright analyst O. Livnat now forecasts that the company will earn ($0.06) per share for the quarter, down from their previous estimate of ($0.05). HC Wainwright currently has a “Buy” rating and a $21.00 target price on the stock. The consensus estimate for Avadel Pharmaceuticals’ current full-year earnings is ($0.51) per share. HC Wainwright also issued estimates for Avadel Pharmaceuticals’ FY2025 earnings at ($0.03) EPS, FY2026 earnings at $0.84 EPS, FY2027 earnings at $1.44 EPS, FY2028 earnings at $1.54 EPS and FY2029 earnings at $1.83 EPS.

A number of other research firms have also recently weighed in on AVDL. Needham & Company LLC restated a “buy” rating and issued a $19.00 price target on shares of Avadel Pharmaceuticals in a research note on Monday, March 3rd. Deutsche Bank Aktiengesellschaft assumed coverage on Avadel Pharmaceuticals in a research note on Tuesday, February 11th. They issued a “buy” rating and a $12.00 price target on the stock. UBS Group dropped their price target on Avadel Pharmaceuticals from $22.00 to $14.00 and set a “buy” rating on the stock in a research note on Monday, January 13th. Finally, Piper Sandler dropped their price target on Avadel Pharmaceuticals from $24.00 to $13.00 and set an “overweight” rating on the stock in a research note on Friday, January 10th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $19.88.

Avadel Pharmaceuticals Trading Up 0.4 %

NASDAQ AVDL opened at $7.91 on Friday. The company has a market cap of $762.22 million, a PE ratio of -10.01 and a beta of 1.28. Avadel Pharmaceuticals has a 12 month low of $7.39 and a 12 month high of $19.09. The stock has a 50 day moving average of $8.62 and a 200-day moving average of $11.43.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of AVDL. Janus Henderson Group PLC boosted its stake in Avadel Pharmaceuticals by 5.7% in the fourth quarter. Janus Henderson Group PLC now owns 14,080,219 shares of the company’s stock valued at $148,117,000 after buying an additional 753,332 shares in the last quarter. Two Seas Capital LP grew its position in Avadel Pharmaceuticals by 90.6% in the fourth quarter. Two Seas Capital LP now owns 4,296,449 shares of the company’s stock valued at $45,156,000 after acquiring an additional 2,042,669 shares during the last quarter. Braidwell LP grew its position in Avadel Pharmaceuticals by 21.2% in the fourth quarter. Braidwell LP now owns 4,105,726 shares of the company’s stock valued at $43,151,000 after acquiring an additional 716,787 shares during the last quarter. Vanguard Group Inc. grew its position in Avadel Pharmaceuticals by 2.3% in the fourth quarter. Vanguard Group Inc. now owns 3,953,247 shares of the company’s stock valued at $41,549,000 after acquiring an additional 90,147 shares during the last quarter. Finally, Wealth Effects LLC grew its position in Avadel Pharmaceuticals by 4.9% in the fourth quarter. Wealth Effects LLC now owns 2,344,130 shares of the company’s stock valued at $24,637,000 after acquiring an additional 110,359 shares during the last quarter. Institutional investors own 69.19% of the company’s stock.

Insiders Place Their Bets

In other news, Director Geoffrey Michael Glass acquired 20,279 shares of the stock in a transaction on Tuesday, December 10th. The shares were purchased at an average price of $9.84 per share, for a total transaction of $199,545.36. Following the transaction, the director now directly owns 75,904 shares of the company’s stock, valued at approximately $746,895.36. This represents a 36.46 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Thomas S. Mchugh purchased 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 11th. The stock was bought at an average price of $10.49 per share, for a total transaction of $52,450.00. Following the transaction, the chief financial officer now directly owns 85,500 shares of the company’s stock, valued at $896,895. This trade represents a 6.21 % increase in their position. The disclosure for this purchase can be found here. Insiders have bought 42,981 shares of company stock worth $400,005 in the last 90 days. Company insiders own 4.80% of the company’s stock.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.